logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics - Results of AGM

RNS Number : 4599P
Silence Therapeutics PLC
10 June 2020
 

 

Results of AGM

 

London, 10th June 2020

 

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that at its Annual General Meeting held on Tuesday, 9th June 2020, all resolutions set out in the notice of meeting were duly passed on a poll.

 

The votes were as follows:

 

Resolution

Votes for

%

Votes against

%

Votes total

% of ISC voted

Votes withheld

1 - Report and accounts

51,506,649

99.4

302,395

0.6

51,809,044

62.6%

13,621

2 - Re-appoint Steven Romano

51,463,539

99.3

359,013

0.7

51,822,552

62.6%

113

3 - Re-appoint auditor and auditor remuneration

51,659,333

99.7

163,219

0.3

51,822,552

62.6%

113

4 - Allot shares

47,496,295

99.9

49,677

0.1

47,545,972

57.4%

4,276,693

5 - Disapply pre-emption rights

46,863,893

98.6

682,079

1.4

47,545,972

57.4%

4,276,693

 

The number of the Company's ordinary shares in issue as at the date of the meeting was 82,796,259 ordinary shares of 5p each.

 

A vote withheld is not a vote in law and has not been counted in the calculation of the proportion of votes for and against the resolutions.

 

Dr. Giles Campion who, as a result of being appointed to the Board after the notice of Annual General Meeting was posted to shareholders, vacated his office as a director at the conclusion of the Annual General Meeting and was re-appointed as a director by the Board immediately thereafter in accordance with the Company's articles of association.  Dr Campion will stand for re-election at the next annual general meeting of the Company in 2021. 

 

Enquiries:

 

Silence Therapeutics plc

Iain Ross, Executive Chairman

Dr Rob Quinn, Chief Financial Officer

 

 

Tel:  +44 (0)20 3457 6900

  Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

  Tel:  +44 (0) 20 7597 5970

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke Partners

Peter Vozzo

[email protected]

 

 Tel: +1 (443) 213-0505

 

Notes to Editors

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGFLFSARAIAIII

Quick facts: Silence Therapeutics PLC

Price: 452

Market: AIM
Market Cap: £374.37 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market Report: FTSE 100 retreats as UK employment tumbles

Headlines from the Proactive UK newsroom. The FTSE100 was on the back foot as the new job numbers highlighted how business is suffering due to the pandemic. The blue chip-index shed 60 to 6,232. People on UK payrolls fell by 649,000 between March and June, according to the government....

3 weeks, 4 days ago